A time to raise awareness about the importance of early and reliable diagnosis of Lyme borreliosis—the most common tick‑borne disease in Europe.

At Seramun Diagnostica GmbH, we support this mission with SeraSpot®, our Spot immunoassay enabling sensitive and specific detection of Borrelia‑specific IgG and IgM antibodies.

A recent study by Ackermann‑Gaumann et al.
“Seroprevalence of Borrelia burgdorferi sensu lato and incidence of Lyme borreliosis in Switzerland”
(Ticks and Tick‑borne Diseases, 2025) highlights the value of SeraSpot® in an epidemiological context.

The study shows that combining modern screening methods with SeraSpot® as a confirmatory assay delivers robust and reliable epidemiological insights, supporting accurate disease surveillance and public‑health decision‑making.

Read the full study here: https://doi.org/10.1016/j.ttbdis.2025.102568